SG Americas Securities LLC Raises Position in Collegium Pharmaceutical, Inc. $COLL

SG Americas Securities LLC grew its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 215.6% during the third quarter, according to its most recent filing with the SEC. The firm owned 28,978 shares of the specialty pharmaceutical company’s stock after acquiring an additional 19,796 shares during the period. SG Americas Securities LLC owned about 0.09% of Collegium Pharmaceutical worth $1,014,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Rubric Capital Management LP grew its stake in Collegium Pharmaceutical by 5.3% in the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock worth $93,374,000 after purchasing an additional 157,743 shares during the period. Emerald Advisers LLC boosted its holdings in shares of Collegium Pharmaceutical by 1.3% during the 2nd quarter. Emerald Advisers LLC now owns 837,549 shares of the specialty pharmaceutical company’s stock valued at $24,766,000 after buying an additional 11,074 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Collegium Pharmaceutical by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 780,243 shares of the specialty pharmaceutical company’s stock worth $23,075,000 after buying an additional 14,709 shares during the period. Millennium Management LLC increased its stake in shares of Collegium Pharmaceutical by 248.5% in the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after acquiring an additional 461,914 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Collegium Pharmaceutical by 13.8% in the 2nd quarter. Bank of America Corp DE now owns 514,807 shares of the specialty pharmaceutical company’s stock worth $15,223,000 after acquiring an additional 62,274 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research firms recently commented on COLL. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Weiss Ratings reissued a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research report on Monday, December 29th. Truist Financial set a $55.00 price target on Collegium Pharmaceutical in a research note on Wednesday, January 7th. Needham & Company LLC raised their price objective on Collegium Pharmaceutical from $48.00 to $56.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Finally, Barclays dropped their target price on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating on the stock in a report on Friday, January 9th. Five analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $52.80.

Collegium Pharmaceutical Stock Performance

COLL stock opened at $45.60 on Monday. The stock’s 50 day simple moving average is $47.10 and its 200 day simple moving average is $39.20. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71. Collegium Pharmaceutical, Inc. has a 12-month low of $23.23 and a 12-month high of $50.79. The stock has a market capitalization of $1.44 billion, a PE ratio of 28.32 and a beta of 0.60.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, November 6th. The specialty pharmaceutical company reported $2.25 earnings per share for the quarter, topping the consensus estimate of $1.89 by $0.36. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The firm had revenue of $209.36 million during the quarter, compared to analysts’ expectations of $191.25 million. During the same quarter in the previous year, the business earned $1.61 earnings per share. The company’s revenue was down 18.9% on a year-over-year basis. As a group, research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insider Transactions at Collegium Pharmaceutical

In other news, CFO Colleen Tupper sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the completion of the transaction, the chief financial officer directly owned 126,667 shares of the company’s stock, valued at $5,133,813.51. The trade was a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Scott Dreyer sold 17,600 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $48.17, for a total transaction of $847,792.00. Following the completion of the sale, the executive vice president owned 103,613 shares in the company, valued at $4,991,038.21. This represents a 14.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 51,250 shares of company stock worth $2,235,352 over the last three months. 2.51% of the stock is currently owned by company insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.